ArticleBMC oral health2025
Isolation, identification, and characterization of Candida species isolated from oral specimens of cancer patients and healthy individuals; a cohort study in Galle District, Sri Lanka.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe incidences of opportunistic fungal infections have dramatically increased in recent years, causing significant mortality rates in hospitalized patients, where immunocompromised populations, such as cancer patients, are being the prime candidates. Candida species are considered the fourth most common cause of nosocomial infections. Over the years, these organisms have developed increased resistance to traditional antifungal agents owing to the widespread overuse of these drugs. This study focuses on the prevalence, antifungal resistance, and characterization of oral Candida colonization in two distinct populations: cancer patients and healthy community individuals.
methodsOral swabs and rinse samples were collected from 170 cancer patients who were admitted and visited the oncology unit of the National Hospital, Galle, Sri Lanka. The same number of healthy individuals was studied as the control group, and Candida isolation, identification, and characterization were carried out by standard microbiological methods. Morphological and physiological characteristics, species distribution, and antifungal susceptibility were investigated.
resultsA total of 220 yeast species were isolated, with 130 from the clinical group and 90 from the community group. Although C. albicans was the predominant oral colonizer in both cohorts, the identification results indicate different non-albicans Candida species profiles across them. Over 73% of the Candida albicans isolates were azole-resistant.
conclusionApart from Candida albicans, non-albicans Candida, such as Candida dubliniensis, Candida parapsilosis, Candida famata, Candida glabrata, Candida krusei, Candida rugosa, Candida pelliculosa, Candida guilliermondii, and Candida utilis were isolated from the oral cavities of cancer patients. Antifungal susceptibility data depict the emergence of azole resistance and amphotericin B resistance in the test population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.